Mizoribine, Tacrolimus, and Corticosteroid Combination Therapy Successfully Induces Remission in Patients with Lupus Nephritis

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2012 Apr 12

PMID 22492013

Citations 3

Authors

Hidetoshi Kagawa

Tsutomu Hiromasa

Takayuki Hara

Ayako Takaki

Ryutaro Yamanaka

Ken-Ei Sada

Hirofumi Makino

Affiliations

Soon will be listed here.

Abstract

Background: Conventional cyclophosphamide-based treatment regimens for lupus nephritis (LN) are still not considered to be optimal. The aim of this study was to evaluate the efficacy and safety of mizoribine, tacrolimus, and corticosteroid combination therapy for LN.

Methods: We retrospectively evaluated a combination treatment of mizoribine and tacrolimus with corticosteroids as induction therapy in eight newly diagnosed systemic lupus erythematosus (SLE) patients with biopsy-proven LN.

Results: All patients were women, and their mean [standard deviation (SD)] age was 48.5 (20) years. All patients (100 %) had positive anti-double-stranded DNA (anti-dsDNA) antibody titers, and four (50.0 %) were nephrotic. Mean (SD) serum creatinine and daily proteinuria levels were 0.72 (0.4) mg/dl (range 0.33-1.55 mg/dl) and 4.56 (2.8) g (range 0.77-8.2 g), respectively. By month 2, significant improvements in the anti-dsDNA antibody titers, levels of proteinuria, serum albumin, and C3, and SLE disease activity index score were observed. By month 6, seven patients (87.5 %) were in complete remission, with normalized levels of both proteinuria and serum creatinine.

Conclusions: This pilot study suggests that mizoribine and tacrolimus treatment with corticosteroids is well tolerated and may prove to be an optimal alternative remission-inducing regimen for LN.

Citing Articles

Optimal treatment targets for lupus nephritis using per-protocol repeat kidney biopsy findings at 2 years and clinical data up to 5 years: a single-center observational study.

Kagawa H, Yamanaka R, Matsubara A, Inoue T, Hayashi R, Kubota N Ther Adv Chronic Dis. 2024; 15:20406223241289074.

PMID: 39420917 PMC: 11483839. DOI: 10.1177/20406223241289074.

Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study.

Ayano M, Kimoto Y, Mitoma H, Akahoshi M, Ono N, Arinobu Y Ther Adv Musculoskelet Dis. 2022; 14:1759720X221096367.

PMID: 35586513 PMC: 9109492. DOI: 10.1177/1759720X221096367.

The first year results of mizoribine/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis.

Kagawa H, Hiromasa T, Yamanaka R, Hayashi R, Tsunashima Y, Inoue T Clin Exp Nephrol. 2018; 22(6):1371-1378.

PMID: 29948442 DOI: 10.1007/s10157-018-1597-8.

References

Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A . Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 2002; 61(12):1065-70. PMC: 1753955. DOI: 10.1136/ard.61.12.1065. View

Bao H, Liu Z, Xie H, Hu W, Zhang H, Li L . Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19(10):2001-10. PMC: 2551567. DOI: 10.1681/ASN.2007121272. View

Waldman M, Appel G . Update on the treatment of lupus nephritis. Kidney Int. 2006; 70(8):1403-12. DOI: 10.1038/sj.ki.5001777. View

Moss K, Ioannou Y, Sultan S, Haq I, Isenberg D . Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002; 61(5):409-13. PMC: 1754082. DOI: 10.1136/ard.61.5.409. View

Mok C, Ying K, Tang S, Leung C, Lee K, Ng W . Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004; 50(8):2559-68. DOI: 10.1002/art.20364. View

Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E . Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin Rheumatol. 2007; 27(1):85-9. DOI: 10.1007/s10067-007-0635-9. View

Boumpas D, Austin 3rd H, Fessler B, Balow J, Klippel J, Lockshin M . Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995; 122(12):940-50. DOI: 10.7326/0003-4819-122-12-199506150-00009. View

Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T . Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol. 2005; 64(1):28-34. DOI: 10.5414/cnp64028. View

Morita Y, Sasae Y, Sakuta T, Satoh M, Sasaki T, Kashihara N . Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol. 2008; 18(4):379-84. DOI: 10.1007/s10165-008-0071-y. View

10.

Houssiau F, Vasconcelos C, DCruz D, Sebastiani G, de Ramon Garrido E, Danieli M . The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2009; 69(1):61-4. DOI: 10.1136/ard.2008.102533. View

11.

Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H . Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996; 28(6):3643-8. View

12.

Houssiau F . Thirty years of cyclophosphamide: assessing the evidence. Lupus. 2007; 16(3):212-6. DOI: 10.1177/0961203306075613. View

13.

Lee T, Oh K, Joo K, Kim Y, Ahn C, Han J . Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010; 19(8):974-80. DOI: 10.1177/0961203310366573. View

14.

Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

15.

Kon T, Yamaji K, Sugimoto K, Ogasawara M, Kenpe K, Ogasawara H . Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. Mod Rheumatol. 2009; 20(2):168-77. DOI: 10.1007/s10165-009-0260-3. View

16.

Maruyama M, Yamasaki Y, Sada K, Sarai A, Ujike K, Maeshima Y . Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol. 2006; 65(4):276-9. DOI: 10.5414/cnp65276. View

17.

Kawasaki Y . Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2010; 2009:681482. PMC: 2801010. DOI: 10.1155/2009/681482. View

18.

Szeto C, Kwan B, Lai F, Tam L, Li E, Chow K . Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008; 47(11):1678-81. DOI: 10.1093/rheumatology/ken335. View

19.

Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J . Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007; 17(3):206-12. DOI: 10.1007/s10165-007-0567-x. View

20.

Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A . Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the tohoku pediatric study group. Nephron Clin Pract. 2008; 110(2):c73-9. DOI: 10.1159/000151721. View